HOUSTON, April 30, 2024 /PRNewswire/ -- Creatv Bio, A
Division of Creatv MicroTech, Inc. (Creatv),
(https://creatvbio.com/) and collaborators were invited to present
clinical data from Creatv's blood test for cancer screening and
diagnostics at the 1st International Conference on
Polyploid Giant Cancer Cells: Biology and Clinical Applications
– held February 16 and 17 at The
University of Texas MD Anderson Cancer
Center in Houston, Texas.
This conference brought together for the first-time
international researchers and clinicians to discuss the biology and
clinical applications of Polyploid Giant Cancer Cells (PGCCs) and
the role they may play in cancer. The Conference featured 28
presentations on PGCCs and more than a dozen posters.
Steven Lin, M.D., Ph.D.,
professor of Thoracic Radiation Oncology at MD Anderson presented
his Polyploid Giant Cancer Cell test data in lung cancer from a
collaboration with Creatv titled "Blood PGCCs in Lung Cancer
Prognosis and Clinical Outcome," showing that PGCCs can
accurately identify patients that will most likely benefit from
PD-L1 immunotherapies in both early-stage and metastatic
disease.
Daniel Gironda, Creatv's
Wake Forest University collaborator and
former Intern, presented his pan-cancer PGCCs results,
"Hypertrophy of Polyploid Cancer Associated Macrophage-Like
Cells (CAMLs) in Circulation Correlates with Multi-Organ Metastatic
Spread in Human Solid Tumors" showing that PGCCs can (i)
predict treatment response within 30 days of receiving a new
therapy in any solid tumor type, (ii) predict a cancer's
aggressiveness and multi-organ metastasis, and (iii) provide a
universal companion diagnostics tool using blood instead of tissue
from patients.
Creatv also presented posters on (1) screening multiple cancers
at the same time by blood test, while demonstrating that the
detection rate of cancer in stage 1 is nearly 80% and (2) showing
data that PD-L1 expression on circulating tumor associated
macrophage polyploids can predict patient outcomes in metastatic
breast cancer.
"The use of biomarkers like PGCCs holds great promise in helping
clinicians determine whether a patient is responding to a specific
therapy in a timely manner," remarked Dr. Cha-Mei Tang, President and CEO of Creatv Bio.
"These results are quite encouraging and give clinicians another
tool to help guide their treatment of cancer patients."
About Creatv Bio
Creatv Bio, a Division of Creatv MicroTech, Inc, is a cancer
screening and cancer diagnostics laboratory for all solid tumors.
In 2014, Creatv was the first group to publish that PGCCs can be
found in the blood of cancer patients and named them circulating
Cancer Associated Macrophage-like Cells (CAMLs). Since this
original publication, our assays and clinical results have been
validated by dozens of independent groups worldwide and in
thousands of patients across an array of solid tumor types.
Please visit our website: https://www.creatvbio.com/
For more information contact:
|
Daniel Adams,
|
|
Ron
Baker
|
|
|
Director of Clinical
R&D
|
|
Chief Business
Officer
|
|
|
dan@creatvmicrotech.com
|
|
ron@creatvmicrotech.com
|
|
|
732-783-7132
(office)
|
|
301-785-5185
(mobile)
|
|
View original
content:https://www.prnewswire.com/news-releases/creatv-bio-presents-cancer-screening-and-cancer-diagnostics-data-at-1st-international-conference-on-polyploid-giant-cancer-cells-302132035.html
SOURCE Creatv MicroTech, Inc.